Aurobindo FDA Monday, January 29, 2024 0.00 Neutral

FDA Approves ISOTRETINOIN — Aurobindo Pharma Limited

# FDA Approves Generic Isotretinoin ANDA from Aurobindo Pharma Aurobindo Pharma Limited received FDA approval for its generic isotretinoin oral formulation (ANDA218194) on January 29, 2024, potentially expanding affordable treatment options in the severe acne market and intensifying competition among existing isotretinoin manufacturers. The approval could pressure pricing for the potent retinoid therapy, which typically commands premium pricing due to its strict regulatory requirements and significant market opportunity.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day